Patents by Inventor Duncan Alexander HAY

Duncan Alexander HAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE
    Publication number: 20240132467
    Abstract: Compounds of general formula (I): (I) wherein R1, R2, R3, R4, R5, Y and Z are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Application
    Filed: June 9, 2023
    Publication date: April 25, 2024
    Applicant: TMEM16A Limited
    Inventors: Stephen COLLINGWOOD, Jonathan David Hargrave, Duncan Alexander Hay, Clive McCarthy, Thomas Beauregard Schofield, Edward Walker, Naomi Went
  • BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS
    Publication number: 20240067653
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Application
    Filed: June 30, 2023
    Publication date: February 29, 2024
    Applicant: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive McCARTHY, Jonathan David HARGRAVE, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD, Naomi WENT
  • Substituted benzodiazoliums as ENaC inhibitors
    Patent number: 11739094
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: August 29, 2023
    Assignee: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive McCarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Naomi Went
  • COMPOUNDS
    Publication number: 20220395512
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: May 17, 2022
    Publication date: December 15, 2022
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases
    Patent number: 11370778
    Abstract: The present invention discloses bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives of formula (I) as inhibitors of ENaC and are of use in the treatment of respiratory diseases and conditions, skin conditions or ocular conditions, wherein the respiratory disease or condition is e.g. cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, including non-cystic fibrosis bronchiectasis, and asthma; the skin condition is e.g. psoriasis, atopic dermatitis and ichthyosis; and the ocular condition is e.g. dry eye disease.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: June 28, 2022
    Assignee: Enterprise Therapeutics Limited
    Inventors: Duncan Alexander Hay, Thomas Beauregard Schofield, Naomi Went, Clive McCarthy
  • Compounds
    Patent number: 11364246
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 21, 2022
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • COMPOUNDS FOR TREATING RESPIRATORY DISEASE
    Publication number: 20220098167
    Abstract: Compounds of general formula (I) and their tautomeric forms all enantiomers and isotopic variants and salts and solvates thereof: wherein represents a single or a double bond and R1, R2, X1, X2, X3, X4, X5, Y and Z are as defined herein; are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Stephen COLLINGWOOD, Clive MCCARTHY, Duncan Alexander HAY, Jonathan David HARGRAVE, Albert MA, Thomas Beauregard SCHOFIELD, Matthew SMITH, Edward WALKER, Naomi WENT, Peter INGRAM, Christopher STIMSON, Someina KHOR
  • MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE
    Publication number: 20220098164
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, A, Z1, Z2 and Y are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Stephen COLLINGWOOD, Jonathan David HARGRAVE, Duncan Alexander HAY, Edward WALKER
  • COMPOUNDS
    Publication number: 20210188855
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Application
    Filed: May 17, 2019
    Publication date: June 24, 2021
    Applicant: Enterprise Therapeutics Limited
    Inventors: Clive McCARTHY, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD
  • BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS
    Publication number: 20210147432
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 20, 2021
    Applicant: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive McCARTHY, Jonathan David HARGRAVE, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD, Naomi WENT
  • Substituted benzodiazoliums as ENaC inhibitors
    Patent number: 10941149
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 9, 2021
    Assignee: Enterprise Therapeutics Limited
    Inventors: Clive McCarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Naomi Went
  • Compounds
    Publication number: 20200383988
    Abstract: Compounds of general formula (1): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the N H calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: November 22, 2019
    Publication date: December 10, 2020
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Buxton, Matthew Habgood, Peter Ingram, Chun Yan Ma, Spencer Napier, Abdul Shaikh, Matthew Smith, Christopher Stimson, Edward Walker
  • COMPOUNDS
    Publication number: 20200361871
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 19, 2020
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Buxton, Matthew Habgood, Peter Ingram, Chun Yan Ma, Spencer Napier, Abdul Shaikh, Matthew Smith, Christopher Stimson, Edward Walker
  • Compounds
    Patent number: 10759785
    Abstract: The invention relates to compounds of general formula (I): wherein R1, R2, R3, R10 and X? are as defined herein. The compounds are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: September 1, 2020
    Assignee: Enterprise Therapeutics Limited
    Inventors: Clive McCarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Naomi Went
  • BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES
    Publication number: 20200239442
    Abstract: The present invention discloses bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives of formula (I) as inhibitors of ENaC and are of use in the treatment of respiratory diseases and conditions, skin conditions or ocular conditions, wherein the respiratory disease or condition is e.g. cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, including non-cystic fibrosis bronchiectasis, and asthma; the skin condition is e.g. psoriasis, atopic dermatitis and ichthyosis; and the ocular condition is e.g. dry eye disease.
    Type: Application
    Filed: October 17, 2018
    Publication date: July 30, 2020
    Applicant: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Duncan Alexander HAY, Thomas Beauregard SCHOFIELD, Naomi WENT, Clive McCARTHY
  • BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS
    Publication number: 20190315757
    Abstract: Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    Type: Application
    Filed: November 22, 2017
    Publication date: October 17, 2019
    Applicant: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive McCARTHY, Jonathan David HARGRAVE, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD, Naomi WENT
  • COMPOUNDS
    Publication number: 20190233402
    Abstract: The invention relates to compounds of general formula (I): wherein R1, R2, R3, R10 and X? are as defined herein. The compounds are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions.
    Type: Application
    Filed: June 21, 2017
    Publication date: August 1, 2019
    Applicant: ENTERPRISE THERAPEUTICS LIMITED
    Inventors: Clive MCCARTHY, Jonathan David HARGRAVE, Duncan Alexander HAY, Thomas Beauregard SCHOFIELD, Naomi WENT